ViroPharma (VPHM +3.4%) trades higher after releasing its 2013 outlook this morning. The company...

|By:, SA News Editor

ViroPharma (VPHM +3.4%) trades higher after releasing its 2013 outlook this morning. The company says it expects net product sales to be between $450M to $475M. Analysts are looking for around $467M. The numbers are encouraging, because Cinryze has become key to the drug developer's future as the it's former blockbuster antibiotic Vancocin is expected to see sales hurt by the potential entry of generic rivals going forward.